Change in 21-gene Recurrence Score result after exposure to neo-adjuvant endocrine therapy in patients with operable breast cancer.

Hilal, Talal; Mi, Lanyu; Ertz-Archambault, Natalie M; Almquist, Daniel R; Anderson, Karen S; Gray, Richard J; Pockaj, Barbara A; Northfelt, Donald W

Hilal, Talal; Mi, Lanyu; Ertz-Archambault, Natalie M; Almquist, Daniel R; Anderson, Karen S; Gray, Richard J; Pockaj, Barbara A; Northfelt, Donald W.

Afiliação

Hilal T; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona.
Mi L; Department of Health Sciences Research, Biostatistics, Mayo Clinic, Phoenix, Arizona.
Ertz-Archambault NM; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona.
Almquist DR; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona.
Anderson KS; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona.
Gray RJ; Department of Surgery, Mayo Clinic, Phoenix, Arizona.
Pockaj BA; Department of Surgery, Mayo Clinic, Phoenix, Arizona.
Northfelt DW; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona.

Breast J ; 26(7): 1449-1451, 2020 07.

Article em En | MEDLINE | ID: mdl-31876083

Assuntos

Neoplasias da Mama; Antineoplásicos Hormonais/uso terapêutico; Neoplasias da Mama/tratamento farmacológico; Neoplasias da Mama/genética; Quimioterapia Adjuvante; Feminino; Humanos; Terapia Neoadjuvante; Recidiva Local de Neoplasia/tratamento farmacológico; Tamoxifeno/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans Idioma: En Revista: Breast J Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google